Neovasc (NSDQ:NVCN) this week touted a newly-published article that described the use of dipyridamole stress perfusion cardiac magnetic resonance to evaluate its Reducer device. The Vancouver-based company’s device is designed to treat refractory angina. The article, published in the Journal of the American College of Cardiology: Cardiovascular Interventions, featured a 66 year old man with angina who […]
Edwards Lifesciences settlement with Boston Scientific lets Neovasc off the hook
Last week’s legal win for Boston Scientific (NYSE:BSX) in its years-long patent battle with Edwards Lifesciences (NYSE:EW) was also a win for Neovasc (NSDQ:NVCN), that company said today. As part of a settlement deal worked out between Irvine, Calif.-based Edwards and Marlborough, Mass.-based Boston Scientific, the Federal Court of Canada dismissed a lawsuit brought by Edwards against Boston, […]
Neovasc dives on Q3 bottom-line miss
Neovasc (NSDQ:NVCN) shares took a hit this morning after the cardiac device maker missed expectations for its third-quarter losses. Vancouver-based Neovasc, which makes the Reducer refractory angina device and the Tiara transcatheter mitral valve replacement, said its losses grew 122.3% to -$12.9 million, or -70¢ per share, as sales fell -65.0% to $480,540 for the three […]
Neovasc touts Tiara TMVR success rate in study
A small study of the Neovasc (NSDQ:NVCN) Tiara transcatheter mitral valve replacement (TMVR) in high-risk patients revealed a 100% procedural success rate and immediate elimination of mitral regurgitation. Published in Circulation: Cardiovascular Interventions, the study also showed no death, myocardial infarction, stroke, major bleeding, or access site complications at 30 days. The twelve patients in the study […]
NeoVasc shares jump on 12-week Reducer data
Neovasc (NSDQ:NVCN) today saw shares jump after it released 12-week data from the first patient implanted with its Reducer device designed for treating refractory angina. The Reducer system is designed to alter blood flow in the heart’s circulatory system to increase perfusion of oxygenated blood to ischemic areas of heart muscle, and can be placed in […]
Neovasc sets date for 1-for-100 reverse split
Neovasc (NSDQ:NVCN) said yesterday it will initiate a 1-for-100 reverse stock split on Friday as it looks to meet the Nasdaq stock market’s minimum bid price requirement. Through the split, the Vancouver-based company will put a single share of its common stock into the hands of each shareholder for every 100 shares they currently possess. The […]
Neovasc talks note holders into another year, announces 1-for-100 reverse stock split
Neovasc (NSDQ:NVCN) said today that holders of its senior secured convertible notes, originally due May 17, 2019, have agreed to extend the maturity of the notes from next year to May 17, 2020, and said yesterday it will initiate a reverse stock split as it looks to regain compliance with minimum bid price requirement of the […]
Shares in Neovasc fall as Q2 shows growing losses
Shares in Neovasc (NSDQ:NVCN) fell today after the medical device maker posted second quarter earnings that showed growing losses. The Vancouver-based company posted losses of $49.1 million, or 4¢ per share, on sales of $405,247 for the three months ended June 30, seeing losses increase a staggering 1032% while sales shrunk 68.9% compared with the same period […]
Neovasc touts Reducer study data
Neovasc (NSDQ:NVCN) today touted results from a study of its Reducer device designed for treating refractory angina. The Reducer system is designed to alter blood flow in the heart’s circulatory system to increase perfusion of oxygenated blood to ischemic areas of heart muscle, and can be placed in a minimally invasive transvenous procedure, the Vancouver-based company said. […]
Neovasc touts first US implantation of Reducer angina device
Neovasc (NSDQ:NVCN) said today that its Reducer device designed for treating refractory angina was used in its first procedure in the US. The Reducer system is designed to alter blood flow in the heart’s circulatory system to increase perfusion of oxygenated blood to ischemic areas of heart muscle, and can be placed in a minimally invasive transvenous […]
EuroPCR Roundup: Biotronik touts two-year study comparing drug-eluting stents
Biotronik yesterday presented two-year data from a trial comparing Boston Scientific‘s (NYSE:BSX) Synergy biodegradable polymer everolimus-eluting stent, Biotronik’s Orsiro sirolimus-eluting stent and Medtronic‘s (NYSE:MDT) Resolute Integrity zotarolimus-eluting stent. Results from the 3,514-patient trial showed no significant difference between the various stents regarding the rate of target vessel failure after two years. But analyses of one-year data found differences between the rates of […]
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 8
- Next Page »
